의료 기술 기업인 RxSight, Inc.(2017년 2월 리브랜딩 이전에는 Calhoun Vision, Inc.로 운영됨)는 조절 가능한 광(빛) 기반 인공수정체(LAL)의 혁신, 제조 및 유통을 전문으로 ...
예상 EPS $-0.29 · 매출 $27.19M · 3 명의 애널리스트
예상 EPS $0.02 · 매출 $55.40M · 3 명의 애널리스트
예상 EPS $-0.94 · 매출 $147.25M · 5 명의 애널리스트
예상 EPS $-0.31 · 매출 $37.97M · 1 명의 애널리스트
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $134.5M | -3.9% | +9.2% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $-38.9M | -41.8% | +23.8% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +76.6% | +8.3% | +0.9% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | -35.8% | -36.0% | +29.3% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | -29.0% | -47.6% | +30.3% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $-19.3M | +13.6% | +1.3% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | -14.4% | +10.1% | +9.7% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 4.0% | -8.4% | -0.8% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 10.95x | -3.6% | -60.1% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $311.8M | -2.1% | +16.0% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | -0.95 vs -1.05 | +9.8% | -0.29 vs -0.29 | -0.1% |
| 매출 서프라이즈 | $134.5M vs $131.6M | +2.2% | $33.7M vs $27.2M | +24.1% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Kurtz Ronald M MD | officer: Chief Medical Officer | Common Stock | D | 5,100 | $6.96 |
| Sep 2, 2026 | Wilterding Mark | officer: Chief Financial Officer | Common Stock | D | 7,765 | $6.96 |
| Sep 2, 2026 | Goldshleger Ilya | officer: Chief Operating Officer | Common Stock | D | 2,041 | $6.96 |
| Sep 2, 2026 | Weinberg Eric | officer: See remarks | Common Stock | D | 2,041 | $6.96 |
| Aug 31, 2026 | Kurtz Ronald M MD | officer: Chief Medical Officer | Common Stock | A | 13,425 | — |
Operator: Thank you for standing by, and welcome to the RxSight Second Quarter 2026 Earnings Conference. [Operator Instructions] I would now like to turn the conference over to Oliver Moravcevic, VP of Investor Relations. Oliver Moravcevic: Thank you, operator. With me on the call today are RxSight President and Chief Executive Officer, Aziz Mottiwala, and Chief Financial Officer, Mark Wilterding. Earlier today, RxSight released financial results for the 3 months ended June 30, 2026. A copy of the press release is available now on the company's website. Before we begin, I would like to remind you that comments and responses to questions during today's call reflect management's views as of today and will include forward-looking and opinion statements, including predictions, estimates, plans, and expectations. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued today and in our filings with the Securities and Exchange Commission or SEC. Our SEC filings can be found on our website or the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements, and we disclaim any obligation to update or revise these forward-looking statements except as may be required by law. We'll also discuss certain non-GAAP financial measures. Disclosures regarding non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, which can be found in the press release. Please note that this conference call will be available for audio replay on our Investor Relations website. With that, I will turn the call over to Aziz. Aziz Mottiwala: Thank you, Oliver, and thank you, and good afternoon, everyone. I'm delighted to be at RxSight and to be speaking with you today. I've spent most of my career in eye care, an area of health care that represents a significant opportunity to make life-changing differences in the quality of patients' lives. Joining a company dedicated to improving people's vision is a tremendous privilege, and in a large part is what attracted me to RxSight. Most recently, as Chief Commercial Officer of Tarsus Pharmaceuticals, I helped build and lead the commercial strategy for one of the most important category-creating products in eye care. That experience reinforced the importance of differentiated innovation, disciplined execution, and strong customer engagement. I look forward to leveraging those experiences as we work to strengthen execution and create value for physicians, patients, employees, and shareholders. I'd like to thank the board of directors for placing its confidence in me, and I also want to acknowledge the entire RxSight team. Over the past 2 weeks, everyone has been incredibly welcoming, and I've been impressed by the spirit of innovation, level of commitment, and problem-solving mindset across the organization. That doesn't …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Eric J. Weinberg | Chief Business Development Officer | USD 2,746,290 | Male | 1961 | Active |
Mark Wilterding | Chief Financial Officer | USD 877,380 | Male | 1978 | Active |
Aziz Mottiwala | President, Chief Executive Officer & Director | USD 834,131 | Male | 1978 | Active |
Ronald Kurtz | Chief Medical Officer | USD 834,131 | — | 1963 | Active |
Ilya Goldshleger | Chief Operating Officer | USD 634,007 | — | 1975 | Active |
Adam Dashe | Executive Vice President of International | — | Male | — | Active |
Patrick Cullen | Executive Vice President of Quality & Infrastructure Operations | — | Male | — | Active |
Maureen O'Connell | Executive Vice President of Clinical & Regulatory Affairs | — | Female | — | Active |
Trent Campbell | Executive VP of US Sales & Commercial Strategy | — | Male | — | Active |
Oliver Moravcevic | Vice President of Investor Relations | — | Male | — | Active |
Jim Schindler | Executive VP & General Counsel | — | Male | — | Active |
BlackRock Inc. acquired a new stake in RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,790,408 shares of the company's stock, valued at approximately $27,910,000. BlackRock Inc. owned 13.99% of RxSight at the end
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
RxSight (NASDAQ: RXST - Get Free Report) and Futureworld (OTCMKTS:FWDG - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Risk and Volatility RxSight has a beta of 1.13, suggesting
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
